NASDAQ:MGNX - Nasdaq - US5560991094 - Common Stock - Currency: USD
Taking everything into account, MGNX scores 3 out of 10 in our fundamental rating. MGNX was compared to 557 industry peers in the Biotechnology industry. MGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MGNX is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.85% | ||
ROE | -70.54% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 89.88% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -7.24 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.28 | ||
Quick Ratio | 3.11 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
1.61
+0.03 (+1.9%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.66 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.28 | ||
P/tB | 1.28 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -24.85% | ||
ROE | -70.54% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 89.88% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 37.16% | ||
Cap/Sales | 1.8% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.28 | ||
Quick Ratio | 3.11 | ||
Altman-Z | -7.24 |